Serina Therapeutics Statistics
Total Valuation
SER has a market cap or net worth of $81.70 million. The enterprise value is $84.03 million.
| Market Cap | 81.70M |
| Enterprise Value | 84.03M |
Important Dates
The last earnings date was Tuesday, May 14, 2024, after market close.
| Earnings Date | May 14, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
SER has 8.41 million shares outstanding. The number of shares has decreased by -67.44% in one year.
| Shares Outstanding | 8.41M |
| Shares Change (YoY) | -67.44% |
| Shares Change (QoQ) | -30.34% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | n/a |
Valuation Ratios
The trailing PE ratio is 7.80.
| PE Ratio | 7.80 |
| Forward PE | n/a |
| PS Ratio | 25.95 |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 26.69 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.64
| Current Ratio | 0.64 |
| Quick Ratio | 0.63 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | 3.01 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -8.00% |
| Return on Capital (ROIC) | -48.62% |
| Revenue Per Employee | $286,227 |
| Profits Per Employee | -$80,922 |
| Employee Count | 11 |
| Asset Turnover | 0.28 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -62.44% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -62.44% |
| 50-Day Moving Average | 9.20 |
| 200-Day Moving Average | 13.77 |
| Relative Strength Index (RSI) | 53.35 |
| Average Volume (20 Days) | 27,918 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, SER had revenue of $3.15 million and -$890,146 in losses.
| Revenue | 3.15M |
| Gross Profit | 3.15M |
| Operating Income | -3.29M |
| Pretax Income | -890,146 |
| Net Income | -890,146 |
| EBITDA | -1.03M |
| EBIT | -1.33M |
| Earnings Per Share (EPS) | $1.25 |
Balance Sheet
The company has $8.76 million in cash and $11.08 million in debt, giving a net cash position of -$2.33 million or -$0.28 per share.
| Cash & Cash Equivalents | 8.76M |
| Total Debt | 11.08M |
| Net Cash | -2.33M |
| Net Cash Per Share | -$0.28 |
| Equity (Book Value) | -4.31M |
| Book Value Per Share | -0.51 |
| Working Capital | -5.12M |
Cash Flow
In the last 12 months, operating cash flow was -$2.19 million and capital expenditures -$518,015, giving a free cash flow of -$2.71 million.
| Operating Cash Flow | -2.19M |
| Capital Expenditures | -518,015 |
| Free Cash Flow | -2.71M |
| FCF Per Share | -$0.97 |
Margins
Gross margin is 100.03%, with operating and profit margins of -104.61% and -28.27%.
| Gross Margin | 100.03% |
| Operating Margin | -104.61% |
| Pretax Margin | -28.27% |
| Profit Margin | -28.27% |
| EBITDA Margin | -32.83% |
| EBIT Margin | -42.34% |
| FCF Margin | -85.98% |
Dividends & Yields
SER does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 67.44% |
| Shareholder Yield | 67.44% |
| Earnings Yield | -1.09% |
| FCF Yield | -3.31% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
SER has an Altman Z-Score of 1.85 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.85 |
| Piotroski F-Score | 3 |